Old Drugs, New Uses: Solving a Hatch-Waxman Patent Predicament

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	McPhie, David C.	en_US
dc.date.accessioned	2012-06-07T20:08:14Z
dc.date.issued	2003	en_US
dc.identifier.citation	Old Drugs, New Uses: Solving a Hatch-Waxman Patent Predicament (2003 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852107
dc.description.abstract	In early 2003, two panels of the Federal Circuit clashed in a pair of cases (Warner-Lambert v. Apotex and Allergan v. Alcon) dealing with the question of whether an action for inducement of infringement could be leveled against a generic drug manufacturer seeking FDA approval for an unpatented drug with both patented and unpatented uses. This paper takes up this debate, analyzing the interpretive puzzles presented in the application of the intricate Hatch-Waxman Act to this set of facts, arguing that the correct interpretation weaves elements from both panelsâ€™ approaches. It finishes with an alternative solution borrowed from a lesson in copyright.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	Hatch-Waxman	en
dc.title	Old Drugs, New Uses: Solving a Hatch-Waxman Patent Predicament	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:08:14Z